Verve Therapeutics, Inc.
Verve Therapeutics, Inc. (VERV) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Verve Therapeutics, Inc. (VERV), featuring income statements, balance sheets, and cash flow data.
Verve Therapeutics, Inc. (VERV) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Verve Therapeutics, Inc. VERV financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $13.08M | $6.87M | $6.69M | $5.70M |
| Cost of Revenue | $1.70M | $1.75M | $1.67M | $1.63M |
| Gross Profit | $11.38M | $5.11M | $5.03M | $4.06M |
| Gross Profit Ratio | $0.87 | $0.74 | $0.75 | $0.71 |
| R&D Expenses | $53.35M | $49.94M | $50.98M | $48.38M |
| SG&A Expenses | $14.10M | $13.84M | $12.88M | $12.53M |
| Operating Expenses | $69.15M | $63.77M | $63.86M | $60.91M |
| Total Costs & Expenses | $69.15M | $63.77M | $65.53M | $62.54M |
| Interest Income | $0.00 | $6.89M | $7.43M | $8.14M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.70M | $1.75M | $1.67M | $1.63M |
| EBITDA | -$54.37M | -$55.16M | -$57.17M | -$55.21M |
| EBITDA Ratio | -$4.16 | -$8.03 | -$8.54 | -$9.69 |
| Operating Income | -$56.07M | -$56.91M | -$58.84M | -$56.84M |
| Operating Income Ratio | -$4.29 | -$8.29 | -$8.79 | -$9.98 |
| Other Income/Expenses (Net) | $6.11M | $6.88M | $9.10M | $8.21M |
| Income Before Tax | -$49.96M | -$50.03M | -$49.74M | -$48.63M |
| Income Before Tax Ratio | -$3.82 | -$7.29 | -$7.43 | -$8.54 |
| Income Tax Expense | $73000.00 | $104000.00 | $66000.00 | $106000.00 |
| Net Income | -$50.03M | -$50.13M | -$49.80M | -$48.74M |
| Net Income Ratio | -$3.83 | -$7.30 | -$7.44 | -$8.56 |
| EPS | -$0.58 | -$0.60 | -$0.59 | -$0.59 |
| Diluted EPS | -$0.58 | -$0.59 | -$0.59 | -$0.59 |
| Weighted Avg Shares Outstanding | $86.87M | $84.23M | $84.23M | $83.13M |
| Weighted Avg Shares Outstanding (Diluted) | $86.87M | $84.63M | $84.23M | $83.13M |
Over the last four quarters, Verve Therapeutics, Inc.'s revenue moved from $5.70M in Q1 2024 to $13.08M in Q4 2024. Operating income in Q4 2024 was -$56.07M, with a strong operating margin of -429%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Verve Therapeutics, Inc. remained robust at -$54.37M, reflecting operational efficiency. Net income rose to -$50.03M, with an EPS of -$0.58. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan